EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support

Dan Qiao, Lei Nie, Shuang Liu, Hai-Bin Ding

Frontiers in Oncology · 17.06.2026 · 16

DOI: 10.3389/fonc.2026.1859304 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 17.06.2026. Verfasst von Dan Qiao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, China. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ado-trastuzumab emtansine (T-DM1) remains an established adjuvant option for patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer and residual invasive disease after neoadjuvant treatment. Severe, persistent thrombocytopenia deviating from the usual cyclic pattern is uncommon and clinically challenging. We report a 50-year-old woman who developed sustained grade 4 thrombocytopenia after three cycles of adjuvant T-DM1, following prior platinum-based chemotherapy and during adjuvant radiotherapy. The thrombocytopenia was refractory to recombinant human thrombopoietin and hetrombopag. Additional evaluations found no evidence of splenomegaly, peripheral platelet destruction, clonal hematologic disease, or a localized radiation effect on the sampled marrow. Sequential marrow evaluations supported megakaryocytic maturation impairment, with initial depletion followed by quantitative recovery but persistently few platelet-producing forms, without dysplasia or fibrosis. Platelet counts repeatedly declined after romiplostim interruption and recovered after reintroduction, allowing long-term stabilization with a threshold-based intermittent regimen. Following multidisciplinary discussion, further anti-HER2 therapy was withheld because of the severely compromised thrombopoietic reserve. As adjuvant antibody-drug conjugate (ADC) strategies continue to evolve, this case suggests that severe non-cyclic thrombocytopenia may occur early during HER2-directed ADC therapy. It supports the value of sequential marrow assessment in selected refractory cases and provides clinical context for individualized romiplostim support in prolonged thrombocytopenia.

Schlagwörter

Stichwörter der Autor:innen

ado-trastuzumab emtansinebreast cancercase reportromiplostimthrombocytopenia

Autor:innen und Institutionen

  • Department of Medical Oncology, Shaanxi Provincial Cancer Hospital, Xi'an, Shaanxi, China.

Zitieren

APA

Qiao, D., Nie, L., Liu, S., & Ding, H. B. (2026). Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1859304

Vancouver

Qiao D, Nie L, Liu S, Ding HB. Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1859304

BibTeX
@article{Qiao2026,
  author = {Qiao, Dan and Nie, Lei and Liu, Shuang and Ding, Hai-Bin},
  title = {Case Report: Persistent severe thrombocytopenia after adjuvant ado-trastuzumab emtansine with sequential bone marrow findings and romiplostim support},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1859304}
}
Kostenlos starten →